Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|January 26, 1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative GroupsR A Zittoun, F Mandelli, R Willemze, et al.
Renal Failure|August 26, 1998
Relation between urinary cytology abnormalities and cyclosporine A therapy in bone marrow transplant recipientsM Sucic, D Boban, M Markovic-Glamocak, et al.
Infection|January 1, 1992
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia GroupH H Gerhartz, R Marcus, A Delmer, et al.
Bone Marrow Transplantation|May 1, 1992
Total body irradiation with or without lung shielding for allogeneic bone marrow transplantationB Labar, V Bogdanić, D Nemet, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Cyclosporin neurotoxicity in patients treated with allogeneic bone marrow transplantationB Labar, V Bogdanic, F Plavsic, et al.
Bone Marrow Transplantation|April 1, 2003
Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?P Rozman, M Karas, A Kosir, et al.
Annals of Hematology|April 1, 1992
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative GroupR Willemze, N van der Lely, H Zwierzina, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Experience with bone marrow transplantation for severe aplastic anemia and leukemia. Two years experience with 31 patients in Zagreb (Yugoslavia)B Labar, V Bogdanic, A Kastelan, et al.
Annals of Hematology|August 1, 1996
2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-ImmunotherapyM Brugiatelli, B Holowiecka, A Dmoszynska, et al.
Annals of Hematology|March 1, 1996
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative GroupT De Witte, S Suciu, D Selleslag, et al.
Pageof 8